Global Dried Blood Spot Collection Cards Market - 2022-2029
The global dried blood spot collection cards market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
Dried blood spot (DBS) is a minimally invasive method for collecting small amounts of blood from a heel stick or finger using a specific application to the filter paper used for testing. DBS samples do not require phlebotomy and can be stored and shipped at room temperature. DBS is used in various clinical settings, including newborn screening (NBS), therapeutic drug monitoring, HIV surveillance, and clinical chemistry applications. Biomarker validation, biomarker development, drug discovery and development, systems biology, and forensic science are other basic research applications for DBS.
Increased government-mandated newborn screening programs, substantial R&D to produce sophisticated treatments, and increased neonatal illnesses and disorders are driving market expansion.
Increased application of dried blood spot testing for HIV surveillance drive the market growth
Key factors expected to drive market revenue growth over the forecast period include increased use of dried blood spot testing in resource-constrained settings, rising demand for newborn screening, increased application of dried blood spot testing for HIV surveillance, and rising prevalence of infectious diseases. In addition, compared to liquid samples, growing automation in analytical laboratories, a lower danger of biohazard, and easier storage are all likely to contribute to market revenue development in the future.
Dried Blood Spots (DBS) is a whole blood collection procedure that involves spotting small amounts of blood on filter paper, drying it, and analyzing it. The method was created to diagnose the inherited metabolic disease phenylketonuria in newborns. The technique is now being tested for various other uses, including pharmacokinetic and toxicological research, as well as therapeutic medication monitoring, to save money during the drug discovery and development process. DBS testing has several advantages over traditional testing, including less invasiveness, a small sample volume requirement, simple storage procedures, inexpensive transportation costs, and a reduced risk of bloodborne pathogens. The popularity of dried blood spot cards has exploded in recent years, expanding the breadth of global health and disease surveillance initiatives in low-resource settings and inaccessible parts of the globe.
Furthermore, the lack of adequate infrastructure for quality-assured venipuncture has increased the demand for dried blood spot cards in countries worldwide. Commercially accessible DBS cards are mostly employed in newborn screening and preclinical drug discovery and development in regulated clinical settings. The Whatman 903 card, manufactured from cotton-based filter paper and housed in a hard cardboard frame, is one of the most popular DBS cards. Another important card is the FTA card, which is made of cotton-based cellulose and contains chemicals that burst cells, denature proteins, and stabilize nucleic acids like DNA, ensuring that the sample is safe for molecular identification. In forensic science, these cards are also widely employed, and this trend is projected to continue over the forecast period.
Advantages such as low blood volume requirements, reduced danger of contamination and biohazards, and long-term storage of blood sports with no deterioration of analytes are further driving market revenue growth.
The high likelihood of collection card contamination is a major impediment to market growth.
The increased risk of contamination of dried blood spots and non-homogeneity can result in inaccurate results and disrupt analytical procedures. The effect of spotting with a capillary or a pipette, the type of card used, and the optimization of extraction are all factors that can influence dried blood spot testing and bioanalysis. Furthermore, the small amount of sample collected for dried blood spot testing can be a limiting factor for analytes requiring large blood volumes. Furthermore, DBS testing results cannot be directly compared to serum or plasma results and necessitate complex assay development for samples. These factors are expected to limit market growth during the forecast period.
COVID-19 Impact Analysis
The recent COVID-19 pandemic, rising newborn screening through dried blood spot collection cards for metabolic disorders, hereditary innovations, and its wide applicability in diagnosing various diseases and new product launches are a few factors attributed to the dried blood spot collection cards market growth. For example, PerkinElmer Inc. introduced the DBS test for COVID-19 in the market in June 2020, utilizing its DELFIA platform with a capacity of up to 5,000 samples per day. This sample collection method allows for both decentralized sampling and efficient testing.
The new born screening segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Due to the increasing efficiency of dried blood spot cards in detecting congenital and metabolic disorders in infants, non-invasive procedures, and easy understanding of follow-up and testing, the newborn screening segment is expected to account for the largest market share in terms of revenue over the forecast period. Furthermore, neonatal screening samples are obtained after birth and before exposure to environmental stimuli, which improves the precision of DBS testing for newborn screening.
Moreover, due to an increasing number of newborn newborns and increased need for newborn screening, dried blood spot (DBS) collection cards in newborn screening are expected to see healthy growth in the future. According to UNICEF, 2.5 million newborns died in their first month of birth in 2018 due to a lack of adequate screening. As a result, there is a need for effective screening in order to meet the increased demand for screening and to prevent future deaths. DBS is frequently used for newborn screening, and it has a number of advantages that make it a good choice. Short diagnosis time, low cost, easy collection and storage, minimally invasive process, excellent precision, and many more advantages are available. Furthermore, the rising prevalence of HIV is supporting market expansion. Several companies have introduced cutting-edge cards for HIV testing and diagnosis. Roche has released Cobas Plasma Separation Cards, which are one of them.
North America region holds the largest market share of the global dried blood spot collection cards market
Due to the increased need for newborn screening, the increasing number of newborn babies, and the rising prevalence of HIV infections, North America is likely to hold a substantial market position in the global dried blood spot collection cards market. Furthermore, technological improvements, several significant competitors, rising healthcare expenditure, rising R&D expenditure, and the presence of well-established healthcare infrastructure contribute to the overall regional market's growth.
For instance, in June 2019, Ahlstrom and GenTegra LLC launched the DBS collection card. This card has offered exceptional DNA protection in DBS for more than 20 years without the need to freeze it. Furthermore, advancements in various blood spot collection cards from established key players, in the United States, are likely to drive the market growth in North America.
The dried blood spot collection cards market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Qiagen, Perkin Elmer, Roche, Shimazdu, Ahlstrom Munksjo, Eastern Business Forms Inc, Centogene AG, Merck among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the dried blood spot collection cards market globally. For instance, In January 2021, Capitainer, a Swedish medical device firm, announced the completion of a USD 3.7 million fundraising round to commercialize its qDBS dried-blood-spot diagnostic equipment. The technology allows users to collect dried blood spots at home using a collection card with a microchannel that creates a high-quality dried blood spot sample for quantitative analysis.
Roche is a biotechnology business that produces medications and diagnostics for the treatment of various diseases. It sells drugs to treat cancer, autoimmunity, central nervous system illnesses, ophthalmological disorders, infectious diseases, and respiratory diseases.
Cobas: Spot a tiny quantity of blood on the card, transport it to a lab where HIV diagnostic tests can be performed, and the cobas® Plasma Separation Card is a stable and easy-to-use sample collection method for HIV plasma viral load. This specially developed card streamlines blood collection and sample transportation by taking a small amount of a patient's blood from a fingertip.
Why Purchase the Report?
Visualize the composition of the global dried blood spot collection cards market segmentation by card type, application, end-user, and region highlighting the key commercial assets and players.
Identify commercial opportunities in the global dried blood spot collection cards market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global dried blood spot collection cards Market-level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global dried blood spot collection cards market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook